This MedLibrary.org supplementary page on Anti-TGF-beta monoclonal antibody GC1008 is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
Anti-TGF-beta monoclonal antibody GC1008 is a monoclonal antibody being studied in the treatment of kidney cancer, melanoma, and pulmonary fibrosis. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Anti-TGF-beta monoclonal antibody GC1008 binds to the protein transforming growth factor-beta (TGFß) and may block the growth of cancer cells that make it. Also called GC1008.
External links
- Anti-TGF-beta monoclonal antibody GC1008 entry in the public domain NCI Dictionary of Cancer Terms
This article includes text from the U.S. National Cancer Institute's public domain Dictionary of Cancer Terms
 |
This oncology article is a stub. You can help Wikipedia by expanding it. |
Wikipedia content modification information:
- This page was last modified on 25 November 2007, at 08:42.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Anti-TGF-beta monoclonal antibody GC1008".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.